Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 486

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer

Open access
Nemunaitis, John, Rabinowe, Susan N., Singer, Jack W., Bierman, Philip J., Vose, Julie M., Freedman, Arnold S., Onetto, Nicole, Gillis, Steven, Oette, Dagmar, Gold, Morris, Buckner, C. Dean, Hansen, John A., Ritz, Jerome, Appelbaum, Frederick R., Armitage, James O., Nadler, Lee M.·1991·New England Journal of Medicine

Abstract

BACKGROUND: The period of neutropenia after autologous bone marrow transplantation results in substantial morbidity and mortality. The results of previous phase I-II clinical trials suggest that recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) may accelerate neutrophil recovery and thereby reduce complications in patients after autologous bone marrow transplantation. METHODS: We conducted a randomized, double-blind, placebo-controlled trial at three institutions. The study design and treatment schedules were identical, and the results were pooled for analysis. One hundred twenty-eight patients were enrolled. Sixty-five patients received rhGM-CSF in a two-hour intravenous infusion daily for 21 days, starting within four hours of the marrow infusion, and 63 patients received placebo. RESULTS: No toxic effects specifically ascribed to rhGM-CSF were observed. The patients given rhGM-CSF had a recovery of the neutrophil count to 500 x 10(6) per liter 7 days earlier than the patients who received placebo (19 vs. 26 days, P less than 0.001), had fewer infections, required 3 fewer days of antibiotic administration (24 vs. 27 days, P = 0.009), and required 6 fewer days of initial hospitalization (median, 27 vs. 33 days; P = 0.01). There was no difference in the survival rate at day 100. CONCLUSIONS: In patients undergoing autologous bone marrow transplantation for lymphoid neoplasia, rhGM-CSF significantly lessens morbidity. Further studies will be required to establish its optimal dosage and schedule of administration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199106203242504

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 486

Metadata

Authors
Nemunaitis, J., Rabinowe, S. N., Singer, J. W., Bierman, P. J., Vose, J. M., Freedman, A. S., Onetto, N., Gillis, S., Oette, D., Gold, M., Buckner, C. D., Hansen, J. A., Ritz, J., Appelbaum, F. R., Armitage, J. O., & Nadler, L. M.
Venue
New England Journal of Medicine
Published
1991-06-20
Volume
324
Issue
25
Pages
1773-1778
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2593892363
Cited by
486
References
17
FWCI
44.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer. https://app.cochat.ai/papers/10.1056/nejm199106203242504
The paper
Nemunaitis, J., Rabinowe, S. N., Singer, J. W., Bierman, P. J., Vose, J. M., Freedman, A. S., Onetto, N., Gillis, S., Oette, D., Gold, M., Buckner, C. D., Hansen, J. A., Ritz, J., Appelbaum, F. R., Armitage, J. O., & Nadler, L. M. (1991). Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejm199106203242504

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.